$ALDX
Aldeyra Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021024943 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.100M $3.000M
YoY Change 3.33% 0.33%
% of Gross Profit
Research & Development $7.726M $6.630M
YoY Change 16.54% -15.53%
% of Gross Profit
Depreciation & Amortization $67.86K $70.00K
YoY Change -3.05% 188.76%
% of Gross Profit
Operating Expenses $7.726M $9.640M
YoY Change -19.85% 22.82%
Operating Profit -$10.83M -$9.638M
YoY Change 12.37% -44.71%
Interest Expense $482.6K $439.8K
YoY Change 9.72% 22316.72%
% of Operating Profit
Other Income/Expense, Net -$458.8K -$229.7K
YoY Change 99.73% -146.2%
Pretax Income -$11.29M -$9.868M
YoY Change 14.41% -41.73%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$11.29M -$9.868M
YoY Change 14.41% -36.84%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$247.4K -$337.9K
COMMON SHARES
Basic Shares Outstanding 29.66M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $138.4M $61.40M
YoY Change 125.48% -25.24%
Cash & Equivalents $138.4M $38.54M
Short-Term Investments $0.00 $22.80M
Other Short-Term Assets $8.600M $1.400M
YoY Change 514.29% -71.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $147.1M $62.80M
YoY Change 134.19% -27.81%
LONG-TERM ASSETS
Property, Plant & Equipment $57.56K $300.0K
YoY Change -80.81% 38.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $233.2K $200.0K
YoY Change 16.59% -82.33%
TOTAL ASSETS
Total Short-Term Assets $147.1M $62.80M
Total Long-Term Assets $233.2K $200.0K
Total Assets $147.3M $63.00M
YoY Change 133.82% -28.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $448.6K $1.100M
YoY Change -59.22% -72.59%
Accrued Expenses $5.372M $3.800M
YoY Change 41.36% -27.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.100M
YoY Change
Total Short-Term Liabilities $11.10M $4.900M
YoY Change 126.53% -48.38%
LONG-TERM LIABILITIES
Long-Term Debt $10.14M $14.70M
YoY Change -31.01%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $10.14M $14.70M
YoY Change -31.01% 7250.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.10M $4.900M
Total Long-Term Liabilities $10.14M $14.70M
Total Liabilities $21.20M $19.60M
YoY Change 8.16% 103.14%
SHAREHOLDERS EQUITY
Retained Earnings -$248.2M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $126.1M $43.47M
YoY Change
Total Liabilities & Shareholders Equity $147.3M $63.00M
YoY Change 133.82% -28.51%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$11.29M -$9.868M
YoY Change 14.41% -36.84%
Depreciation, Depletion And Amortization $67.86K $70.00K
YoY Change -3.05% 188.76%
Cash From Operating Activities -$13.47M -$15.36M
YoY Change -12.29% 21.59%
INVESTING ACTIVITIES
Capital Expenditures $7.806K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $6.220M
YoY Change -32.17%
Cash From Investing Activities -$7.806K $6.224M
YoY Change -100.13% -32.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $70.05M $3.173M
YoY Change 2107.8% 292.87%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 74.06M 3.253M
YoY Change 2176.79% 698.07%
NET CHANGE
Cash From Operating Activities -13.47M -15.36M
Cash From Investing Activities -7.806K 6.224M
Cash From Financing Activities 74.06M 3.253M
Net Change In Cash 60.58M -5.883M
YoY Change -1129.84% 92.26%
FREE CASH FLOW
Cash From Operating Activities -$13.47M -$15.36M
Capital Expenditures $7.806K $0.00
Free Cash Flow -$13.48M -$15.36M
YoY Change -12.24% 21.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M13D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M1D
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8630543
CY2021Q1 us-gaap Assets Current
AssetsCurrent
147072922
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
175619
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57559
CY2021Q1 us-gaap Assets
Assets
147306100
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
448591
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5371681
CY2021Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
5094938
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248205590
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
126074472
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
147306100
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3004841
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9638444
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
210100
CY2020Q1 us-gaap Interest Expense
InterestExpense
439816
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-229716
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9868160
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29210889
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
51728
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
51728
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9816432
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
70049450
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4004290
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
9875
CY2021Q1 aldx Net Loss
NetLoss
-11289862
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
126074472
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
43472520
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-11289862
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-9868160
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2381656
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1953652
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
141505
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
141505
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
67220
CY2021Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
67863
CY2020Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
72040
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3429586
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-429321
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
66953
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
264595
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1410270
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8285485
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13471741
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15359752
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7806
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
5776090
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10270
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
9875
CY2020Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
69889
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3252983
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5882859
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38542971
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NATURE OF BUSINESS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the “Company” or “Aldeyra”), a Delaware corporation, is a clinical-stage biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s principal activities to date include raising capital and research and development activities. </p>
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company’s management evaluates its estimates and assumptions on an ongoing basis. Management’s most significant estimates in the Company’s consolidated financial statements include, but are not limited to, estimates related to clinical trial accruals, estimates related to prepaid and accrued research and development costs, acquired in-process research and development (“IPR&amp;D”) expense, contingent liabilities, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </p>
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6653462
CY2021Q1 us-gaap Cash
Cash
84073606
CY2021Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4368773
CY2021Q1 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
50000000
CY2020Q4 aldx Cash Equivalent Reverse Repurchase Agreement
CashEquivalentReverseRepurchaseAgreement
25000000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77858311
CY2021Q1 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2021Q1 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
8277148
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
4793794
CY2021Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
137569
CY2021Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
215826
CY2020Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
407163
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8630543
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5200957
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2387916
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1323138
CY2020Q4 aldx Accrued Contingent Consideration Payable In Stock Current
AccruedContingentConsiderationPayableInStockCurrent
2500000
CY2021Q1 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2343210
CY2020Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3944094
CY2021Q1 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
640555
CY2020Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
367533
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5371681
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8134765
CY2021Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2020Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
15000000
CY2021Q1 aldx End Of Term Charge
EndOfTermCharge
534556
CY2020Q4 aldx End Of Term Charge
EndOfTermCharge
445464
CY2021Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
298819
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
351232
CY2021Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
5094938
CY2020Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
3659776
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10140799
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11434456
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3659776
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
5931718
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6451006
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
16042500
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2020 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2019 aldx Share Based Compensation Arrangement By Share Based Payment Award Granted Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedPeriod1
P4Y
CY2021Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1400000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2547247
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.65
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15863925
CY2021Q1 us-gaap Share Price
SharePrice
11.88
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3856204
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.72
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23774646
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2381656
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1953652
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4608311
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.73
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
108115
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.24
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
543826
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.36
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
316396
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.23
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
200000
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
182345
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6726
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
175619
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
175619
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
175619
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
182345
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
182345

Files In Submission

Name View Source Status
0001564590-21-024943-index-headers.html Edgar Link pending
0001564590-21-024943-index.html Edgar Link pending
0001564590-21-024943.txt Edgar Link pending
0001564590-21-024943-xbrl.zip Edgar Link pending
aldx-10q_20210331.htm Edgar Link pending
aldx-10q_20210331_htm.xml Edgar Link completed
aldx-20210331.xsd Edgar Link pending
aldx-20210331_cal.xml Edgar Link unprocessable
aldx-20210331_def.xml Edgar Link unprocessable
aldx-20210331_lab.xml Edgar Link unprocessable
aldx-20210331_pre.xml Edgar Link unprocessable
aldx-ex311_6.htm Edgar Link pending
aldx-ex312_7.htm Edgar Link pending
aldx-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending